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Effect of probucol on hypercholesterolemia in renal transplant transplant patients treated with PSL and cyclosporine
patients. A, a selected subset of these patients showing hypercho-
Background. Hypercholesterolemia is a well-known compli- lesterolemia was prospectively treated with probucol [6].cation in kidney transplant recipients, although its pathogenesis
may be multifactorial. The therapeutic effect of probucol on
post-transplant hypercholesterolemia was prospectively evalu-
METHODSated.
Methods. Twelve hypercholesterolemic kidney transplant Thirty-seven renal transplant patients immunosup-
patients with serum total cholesterol $250 mg/dl without diabe- pressed with PSL and cyclosporine A and who had serum
tes mellitus or hypoproteinemia were prospectively treated creatinine (Cr) levels of less than 3 mg/dl satisfied thewith probucol (250 mg, bid, for three months). Before initiating
inclusion criteria for this study. None were diabetic pa-and at the end of treatment, blood was drawn after at least a 12-
tients or demonstrated hypoproteinemia or proteinuria.hour fast to measure lipids in serum and lipoprotein fractions,
apoproteins (apo), lipoprotein fractions, lethicin cholesterol Twelve (five women and seven men, aged 29 to 51 years,
acyl transferase (LCAT), free fatty acids (FFAs), and choles- mean age 6 sem, 34.2 6 2.5 years) of the 37 patients
terol ester. The lipid profiles of 17 healthy subjects were also
whose serum total cholesterol level was 250 mg/dl orexamined.
higher were submitted to a prospective treatment withResults. After treatment with probucol, serum total choles-
terol, low-density lipoprotein (LDL) cholesterol, high-density probucol (Sinlestalt; 250 mg, bid, for three months; Daii-
lipoprotein (HDL) cholesterol, and apo AI were significantly chi Seiyaku, Co., Tokyo, Japan) after obtaining their
decreased, whereas cholesterol ester increased significantly. informed consent. Their donor sources were living re-
Conclusions. Post-transplant hypercholesterolemia is fea-
lated in six patients and cadaveric in six. PSL was startedtured with abnormalities in very low-density lipoprotein
at 1 mg/kg body wt and was then gradually decreased(VLDL) metabolism. Although HDL cholesterol decreased,
probucol might have acted as an antiatherogenic by modulating to the maintenance dose of 0.2 mg/kg. Cyclosporine was
HDL metabolism and stimulating reverse transfer of choles- begun at 6 mg/kg and was then tapered to 3 to 4 mg/
terol from peripheral tissue. kg within three-months post-transplant. The follow-up
period after transplantation ranged from 5 to 76 months
(mean 37.4 6 4.9 months), and the latest serum Cr levelsHyperlipidemia is a well-known complication in kid-
ranged from 0.9 to 2.9 mg/dl (mean 1.9 6 0.5 mg/dl).ney transplant recipients. However, opinions in the liter-
Before starting and after completing probucol adminis-ature differ concerning the prevalence and the type of
tration, venous blood was drawn after at least 12-hourlipoprotein abnormalities. Reported changes of serum
fasting. Serum was separated at room temperature, andlipids include an increase in total cholesterol and triglyc-
the total cholesterol, TG, and phospholipid (PL) levelseride (TG) levels, as well as an increase in very low-
immediately measured with an autoanalyzer. Apos A,density lipoprotein (VLDL) and LDL cholesterol con-
B, CII, CIII, and E were determined by cytochrometents [1, 2]. These changes may be causally related to
immunoassay, lipoprotein fraction by ultracentrifuga-multiple factors, including medication, such as predniso-
tion, lethicin acyl transferase (LCAT) by liposome sub-lone (PSL) [3] and cyclosporine [4, 5], the patients’ age
strate assay, and free fatty acids (FFAs) by colorimetry.and sex, and level of renal function [2]. To clarify further
Cholesterol ester was calculated as percentage choles-the lipoprotein and apoprotein (apo) profile in renal
terol ester ratio. The lipid profiles of 17 (10 females and
7 males) age-matched (24 to 59 years of age, mean 36.8 6
Key words: apoprotein, cyclosporine A, lipoprotein. 1.6 years) healthy subjects were also examined. Data
are shown as mean 6 sem. Statistical differences were 1999 by the International Society of Nephrology
S-229
Okubo et al: Effect of probucol on post-transplant hypercholesterolemiaS-230
Table 1. Lipid in serum and lipoprotein fractions, apolipoproteins, between cholesterol ester and VLDL cholesterol ob-
LCAT, FFA and cholesterol-ester in 12 hypercholesterolemic
served in normal controls was lost (data not shown).transplant patients before and after treatment with probucol
These data may be compatible with the deranged reverse
Before treatment After treatment transfer of cholesterol from peripheral tissue, although
mg/dl no direct evidence on the role of cyclosporine A was
Serum obtained from this study.
T-CHL 27266.9 240610.7a Probucol [6], known to have important antioxidant
TG 197631.7 240658.6
properties, was given to cyclosporine A-treated renalPL 26166.3 220618.2a
VLDL transplant patients by Gallego et al, as well as to our
Protein 12.262.09 14.163.64 patients, in an attempt to modulate hypercholesterol-
CHL 32.266.04 40.5613.0
emia [7]. The drug decreased the levels of both serumTG 125630.5 159651.7
PL 40.768.34 48.9615.3 total cholesterol and LDL cholesterol. Also, a concur-
LDL rent decrease in HDL cholesterol level was observed, as
Protein 71.063.44 61.164.05a
was previously reported by Matsuzawa et al [8]. TheyCHL 17969.1 154610.5a
TG 48.464.87 56.867.31 showed that probucol stimulated the reverse transfer of
PL 11566.0 96.966.29a CHL from peripheral tissue to HDL. Although we have
HDL
no data of our own regarding the effects of probucol onProtein 22865.7 206610.5
CHL 59.463.96 45.065.24a the reverse cholesterol system, it may have caused a
TG 23.661.73 23.663.06 decrease in the serum HDL level and a contraction of
PL 10566.72 83.068.46a
atheromatous plaque in the vessel wall [8]. IncreasedApoprotein
AI 15866.1 13469.3a levels of cholesterol ester following probucol treatment
AII 35.861.20 30.862.18 are compatible with an enhanced HDL reverse transfer.
B 14164.1 13269.20
Through this mechanism, probucol may reduce athero-CII 7.461.03 7.861.50
CIII 27.862.41 31.665.60 genesis, although it lowers HDL cholesterol. Its long-
E 7.460.64 7.460.93 term effect on renal transplant patients remains to be
LCAT 89.965.58 81.063.58
determined.FFA 0.7460.10 0.8560.11
CHL-ester % 74.560.31 75.960.51a
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